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`Treatment is not yet necessary’: delays in seeking access to HIV-treatment in Uganda and 
Zimbabwe 
 
Abstract 
We examine the logic that individuals use to account for the delay to go for an HIV test and/or to 
initiate HIV treatment. Our qualitative study, situated within the REALITY trial (Reduction of 
Early Mortality in HIV infected adults and children starting antiretroviral), was conducted in 
Uganda and Zimbabwe in 2015. Forty-eight participants (different age groups, sex, viral 
load/WHO disease stage) were included. Each participant had two interviews (one after 4 weeks 
of participation in the trial the other after 12 weeks). If a person could manage presenting 
symptoms, they felt they had “more time” before starting ART.  Their reluctance to have an HIV 
test (despite deteriorating health) arose from a belief that they were not `sick’, that treatment was 
`not yet necessary’. People in our study did not consider themselves as presenting ‘late’, and 
treatment was not considered urgent as long as they considered their health to be `good enough’.  
KEYWORDS: HIV; antiretroviral therapy; Universal Test and Treat; treatment delays; Uganda; 
Zimbabwe; Africa 
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Introduction 
By the end of 2016 it was estimated that 19.5 million of the 36.7 million people living with HIV 
globally were accessing anti-retroviral therapy (ART) (UNAIDS, 2017).  Despite the enormity of 
progress in providing access to treatment, receiving a positive HIV-test result and being 
encouraged to start ART as soon as possible may still present a significant challenge.  
  
Access to HIV treatment sustains health, but for someone who may not feel ill or question an HIV-
positive test result `their perceptions of their life-worlds’ may not include any acknowledgement 
that they need any form of treatment (Takahashi, Wiebe, & Rodriguez, 2001, p. 847).  There is a 
fine line between sickness and health: being healthy may be an ability to adapt and self-manage 
(Huber et al., 2011). For some people living with HIV who may not have been tested, or for those 
who have been tested but choose not to start treatment, this self-management continues while any 
form of ill-health can be contained.  Starting ART is an acceptance that for adaptation and self-
management to continue, the time has come for external support (Russell et al, 2016) and health 
can only be sustained by taking treatment. 
 
Wilton (1996) noted in his ethnography among nine symptomatic HIV-positive men (from a high-
income setting) not yet on ART, that the efforts involved in incorporating the changing material 
and perceived parameters of daily life with HIV, required a considerable realignment of 
individuals’ ‘life worlds’. Although encompassing different routines and threats, this remains true 
for those now living with HIV on ART, given their perceived fragility of health and the time 
investment required to engage in long term clinical care to maintain their health (Winchester et al., 
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2017). Much has been written about the current manageability of an HIV diagnosis, however 
reconciling oneself to the altered realities of living with HIV, even within the sustained health 
offered by ART, may still take time (Mutabazi-Mwesigire, Seeley, Martin, & Katamba, 2014; 
Russell & Seeley, 2010). Reconciling the health-illness tension into self-identity (Takahashi et al., 
2001) may be compounded by the risk of being identified by others as ‘ill/ HIV-positive” if seen 
to be attending a clinic.  This fear can be particularly prominent when there is no other health 
explanation that they could plausibly give for their utilization of medical services (Treves-Kagan 
et al., 2016).  
 
Time and timeliness are pivotal factors in whether the current HIV prevention and treatment 
agendas of ‘test and treat’ (immediate treatment on diagnosis) and ‘treatment as prevention’ 
(reduced viral load as a result of taking treatment, thus reducing infectivity) will be successful 
(Dieffenbach & Fauci, 2009; WHO, 2012, 2016). The concept of ‘timeliness’ is framed through a 
biomedical lens and operates on the assumption that there is a shared understanding between 
patient and clinician about how time is experienced, measured and consumed. It is relatively rare 
to consider a more emic perspective on what might constitute an individual’s criteria for when the 
‘right time’ to initiate treatment is and what might underpin their definition of timeliness.  
 
In general, the exploration of time as a critical dimension in shaping health-seeking behaviour and 
the ways in which it shapes health has been relatively neglected (Strazdins et al., 2011). Notable 
exceptions to this are the body of chronic illness research which has focused on time as a resource 
for accessing care and the competing priorities and commitments which impede the time a person 
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may have to seek treatment (Dempsey, Dracup, & Moser, 1995; Schoenberg, Peters, & Drew, 
2003). Although increasing attention is paid to refusals (Katz & Bangsberg, 2016; Katz et al., 
2015) and ‘lateness’ in relation to ART (see, for example, Kigozi et al., 2009; Mocroft et al., 2013; 
Moreno, Mocroft, & Monforte, 2010; Mukolo, Villegas, Aliyu, & Wallston, 2013; Parrott et al., 
2011), given the role time plays in the successful execution of the broad HIV prevention and 
treatment agenda, understanding what ` late’ might mean for an individual has not received so much 
attention. Clinically there is variation in how quickly some individuals need to get onto ART 
having been infected, with some people with an infection that progresses slowly effectively having 
‘more time’ to initiate treatment. However the clinical messaging, which now focuses on getting 
everyone onto ART as soon as possible, can not necessarily engage with the nuances of this 
variation. It is important to pay attention to the divergence between this global clinical policy and 
how the urgency and necessity of starting treatment is interpreted by those that this policy aims to 
reach.  
 
An irony of the success of ART is that it can render HIV, and thus its own necessity, invisible. 
What is still visible are some of the physical scarring and side-effects associated with earlier ART 
options.  The effects of lipodystrophy (the redistribution of body fat) caused by some earlier drug 
regimens (Staszewski et al., 1999) may continue to embody to some within the community the 
risky consequences, both physical and social, of being treated for HIV (Katz et al., 2015).  
 
Therefore, the concealment of the daily success of ART treatment for those who initiated treatment 
before becoming symptomatic, may mean that there is a time lag between the newer realities of 
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life on ART and the outdated but still prevailing social norms about the compromised health and 
social status of those on ART.  Seen through this lens, rather than that of the clinical evidence, if 
their untreated HIV remains personally manageable, the incentives for early treatment to maintain 
relative health may be less compelling. An ambiguity may still exist for them in whether immediate 
ART is the route to healthiness (Curran et al., 2014).   
 
With the advent of `test and treat’, a person `delays’ treatment if they do not start ART soon after 
their HIV-positive diagnosis being confirmed.  There has been a rapid change in policy about when 
is the ‘right time’ to initiate HIV treatment (Insight Start Study Group, 2015), and the subsequent 
incentives for ‘timely’ presentation for diagnosis and treatment. Is this information being 
incorporated into the decisions and actions about treatment and provoking a recalibration of an 
individual’s expectations of what their life might be to live with HIV through being on ART 
(Russell et al., 2016; Sprangers & Schwartz, 1999)? In this paper, we examine the logic that 
individuals who presented very late for treatment (CD4<100 cells/mm3) use to account for the 
time they took to go for an HIV test and/ or to initiate HIV treatment. 
 
The REALITY trial (Reduction of EArly mortaLITY in HIV-infected adults and children starting 
antiretroviral therapy) was conducted in nine centres in four countries (Kenya, Malawi, Uganda 
and Zimbabwe). This was a randomized controlled trial with the primary objective of identifying 
effective, safe and acceptable interventions to reduce early mortality in HIV-positive adults, 
adolescents, and older children (five years or more) initiating anti-retroviral therapy (ART) with 
CD4<100cells/mm3. Three methods were used to reduce early mortality following ART initiation: 
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(i) increasing the potency of ART with a 12 week induction period; (ii) augmented prophylaxis 
against opportunistic/bacterial infections and helminths for 12 weeks  and (iii) ready-to-use 
supplementary food for 12 weeks. Each intervention was compared with standard of care (Hakim 
et al., 2017). 
 
In response to addressing the trial research question about reducing early mortality among those 
initiating ART, a qualitative sub-study was undertaken to find out the reasons why participants 
presented late for HIV treatment. This sub-study was conducted at two sites in Uganda: Gulu 
(northern Uganda) and Mbarara (south western Uganda), and the site in Harare, Zimbabwe. 
Methods 
Study Population and Sampling 
Forty-eight participants enrolled in the REALITY Trial participated in the qualitative sub study in 
2015. Males and females aged 10 years and above were recruited, 24 from Uganda and 24 from 
Zimbabwe. Purposive sampling was used to include participants randomized from the two extreme 
arms in the trial; half on the intervention arm which combined all three interventions being 
investigated namely, participants receiving both enhanced ART and anti-infection treatment plus 
ready to use food supplements for 12 weeks and the other half receiving none of the interventions 
where participants received  standard of care. The qualitative sample was designed to be as 
representative as possible of the various age groups and gender of the trial population.   
The REALITY social science study was conducted in research settings in Mbarara and Gulu, two 
of the four REALITY trial sites in Uganda. The Mbarara site is located within a research facility 
in the regional referral hospital where there is a department which handles HIV testing and 
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treatment which receives many patients from within Mbarara and neighbouring districts. The 
Gulu site was based in a specialist research clinic which provides for patients from Gulu and 
neighbouring districts.   
In Zimbabwe the REALITY trial site was in Harare, in a centre set up for clinical research situated 
within a referral hospital. Participants came from Harare and the surrounding areas.  
 
Data collection and Analysis 
Two interviews were conducted with each participant; phase 1 interviews were conducted after the 
participants had been in the trial for four weeks to learn about their life before ART and how they 
came to join the REALITY trial. Phase 2 interviews were conducted after the 12 week intervention 
had concluded to find out about the adjustment processes that followed being initiated on ART. 
Topics that were discussed included adherence, disclosure and social support systems that were 
available to the participants once they started HIV treatment. Participants were asked about their 
illness history and what prompted them to take an HIV test, to understand what factors may have 
influenced the decision to test for HIV and what steps they took after the HIV test to seek treatment 
and care. Although all trial participants were initiated onto ART when enrolled into the trial, some 
participants who tested positive at the start of the trial may have received a positive test result at 
an earlier point, but not initiated treatment. For those participants who had had prior confirmation 
of their HIV-positive status we asked them why they had not sought treatment soon after receiving 
a positive test result.  
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All the interviews were audio recorded, transcribed verbatim and translated from local languages 
into English. A grounded analytic approach to thematic analysis was adopted, using systematic 
case comparison, including across study sites and key sampling dimensions such as gender and 
age, and negative case analysis throughout (Strauss & Corbin, 1994).  Core themes which emerged 
through our first level (participant description) and second level (concept-driven categories) 
coding included: good enough health; consumption of time; curtailed ‘choices; and community 
discourses about anti-retroviral treatment.  
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Findings  
Table 1 below shows details of participants by age and sex as well as WHO Stage at presentation 
(see supplementary material for Table 2 including viral load and CD4 count data).  We have used 
WHO stage in this table, because how ill someone felt was a very important factor in whether a 
person presented for testing. Those presenting with Stage 4 symptoms were often very ill indeed. 
Table 1. Study participant country, age, sex, Marital status, HIV status before REALITY 
trial and WHO disease stage on first visit to study clinic 
Country Age Sex Marital Status Aware of HIV 
status 3 months 
before REALITY 
trial 
WHO Stage* 
Uganda 39 F Single Yes  1 
Uganda 30 M Single Yes 1 
Uganda 32 F Single Yes 1 
Uganda 38 F Married No 1 
Zimbabwe 31 M Married No 1 
Uganda 36 F Married Yes 1 
Uganda 36 M Married No 1 
Uganda 38 F Single Yes 1 
Uganda 50 M Married Yes 1 
Uganda 40 M Married No 1 
Zimbabwe 40 M Married  No  1 
Uganda 24 F Married Yes 1 
Uganda 47 M Single No 1 
Uganda 30 F Single Yes 1 
Uganda 50 F Single Yes 1 
Zimbabwe 12 M  Single  Yes  2 
Zimbabwe 46 M Married  Yes  2 
Uganda 30 M Single Yes 2 
Uganda 32 F Single No 2 
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Zimbabwe 17 M Single  No  2 
Zimbabwe 33 F Single  No  2 
Uganda 30 F Single Yes 2 
Zimbabwe 38 F Divorced  Yes  2 
Uganda 26 M Married Yes 2 
Zimbabwe 29 M Single  No  2 
Zimbabwe 53 F Divorced  Yes  3 
Zimbabwe 42 M Married  No  3 
Zimbabwe 33 M Widowed   Yes  3 
Zimbabwe 12 F Single  Yes  3 
Zimbabwe 40 M Married  Yes  3 
Zimbabwe 57 F Married  Yes  3 
Uganda 39 M Married Yes 3 
Zimbabwe 32 F Divorced  Yes  3 
Uganda 63 M Married Yes 3 
Zimbabwe 35 F Widowed  No  3 
Zimbabwe 44 M Divorced  No  3 
Zimbabwe 29 M Married  Yes  3 
Zimbabwe 43 M Divorced  No  3 
Uganda 52 M Married Yes 3 
Zimbabwe 53 F Widowed  No  3 
Zimbabwe 46 F Married  No  4 
Zimbabwe 51 M Married  No  4 
Zimbabwe 47 F Divorced  Yes  4 
Uganda 38 M Single No 4 
Uganda 28 M Single No 4 
Zimbabwe 32 F Divorced  Yes  4 
Uganda 23 F Single Yes 4 
Uganda 19 M Single No 4 
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* See http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf for an explanation of the 
staging 
 
‘Late’ presentation: 
By definition, all participants in the trial had low CD4 cell counts (<100 cells/mm3), but a 
substantial number were very low (<50 or even <10 cells/mm3). Viral loads were also very high 
(Table 2). However, these laboratory test results were not known to participants. In contrast, 
several participants presented for HIV testing with many symptoms. The deterioration of their 
health tended to have been gradual, which meant that they were able to ignore or minimise the 
significance of their worsening condition. Accounting for why they presented late for HIV testing, 
many stated that they thought that their illness was just `ordinary’ and or `minor ailment’ which 
would resolve by itself or with self-medication.  
I would mainly feel weak and buy tablets to gain energy and sometimes I would fail to eat 
food (no appetite). I was a very fat woman weighing 90kgs but then I noticed I was losing 
weight and all my clothes would fall off so I always wondered what might be the 
problem…just losing weight, itching all over and I would just think that maybe it is an illness 
probably Candida so I would buy tablets and insert there (vagina). I was suspecting diseases 
such as syphilis and not HIV. (Female, 50 years, Uganda). 
An intrinsic thread within many participants’ accounts was an expectation that it was not 
uncommon for their health to be compromised to varying extents at different points.  Some adverse 
physical symptoms were to be anticipated and if they were manageable then this did not disrupt 
their sense of ‘healthiness’. Health was thus defined as an absence of a debilitating physical 
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condition, rather than as a fulfilment of an ideal physical state.  Two men, both WHO stage 3, 
demonstrated this when they said:     
It never came into my mind [that it was HIV-related] […] it’s common for one to get sick 
here and there then you get well and get back to your daily life, you start doing what you 
were doing or just doing your work. (Male, 43 years, Zimbabwe) 
So, these are the kind of things [illness] you expect as a living being. Trees do lose their 
leaves at some point and so you may think that it is just something people experience and it 
will what? It will come to pass. That is the "belief" I had, that it’s nothing serious and that 
it is a phase which will eventually go away on its own. (Male, 42 years, Zimbabwe). 
In the face of evident ill-health and in a society where there is a relatively high risk of acquiring 
HIV, participants reporting having considered their health problems at the time to still be 
manageable. For as long as it was feasible, they had treated the presenting symptoms at general 
clinics or through using herbal treatment. For instance, a 38 year old man in Uganda (WHO stage 
4), said: 
I used to be sick and would feel so weak but was using herbal medicine. I had a skin rash 
and lots of blisters so I would self-medicate…knowing that it was syphilis, I went to the 
hospital and they also tested it and treated syphilis. 
A 36 year old man (WHO Stage 1), also from Uganda, commented: 
I would get treatment for malaria and cough but they wouldn’t cure fast; they get cured 
for one month and recur again. I was buying it (treatment) in small towns where there are 
clinics with drugs. But I noticed that my energy was becoming low.  
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Not late, instead not yet necessary:  
Prior to getting to the point of testing and getting treatment, most of the participants reported being 
aware of their own risk of becoming or already being HIV-positive. Consequently, the focus on 
alternative causes and treatment courses was often in contradiction with the information that they 
had about their own likelihood of having become HIV-positive. The probability of being HIV-
positive themselves was usually grounded in knowing that their partner had previously been 
diagnosed as HIV-positive.   
Some participants in relationships were aware of their sexual partner’s HIV-positive status, 
however they were reluctant to acknowledge that they may also be HIV-positive. This was 
particularly common among men. They described not being ready to consider themselves ill and 
to accept and reconcile themselves to having an altered status of liminal health. For men in the 
study, for whom the act of testing and then being labelled (or self-identifying) as HIV-positive, 
this seemed to constitute an affront to their embodiment of masculinity through their consequent 
compromised strength and health.  This reticence to realign their understanding of their perceived 
‘healthiness’ further delayed the act of testing or accepting the need to start treatment.  
She [his wife] would tell me to go and take a test but I would tell her that I have not yet 
reached that time, deep down I feared. (Male, 40 years, Uganda, WHO Stage 1) 
My wife forced me…you go [laughs]. I would be in doubt but she told me to go [and test] 
because she tested and found that she is infected. (Male, 50 years, Uganda, WHO Stage 1) 
A 46 year old woman from Zimbabwe, talked about how her husband was resisting testing when 
she disclosed her status that she was already initiated on ART.  
I came back from the hospital and told my husband and showed him my hospital cards and 
he just said okay. I told him that he also must be tested because that is what they told me 
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at the clinic and he just said I am not sick. Each time I go for my review they ask me if he 
was tested and I keep on saying no and they keep on asking saying he must be tested. 
The delay to act to first confirm their own positive HIV status through testing and then to initiate 
treatment was explained by considering that they had ‘more time’ before it became necessary to 
start ART. Treatment was not yet necessary because they considered that they were relatively 
successful in managing their symptoms, which enabled them to define the source of any ill-health 
as being something, anything, other than HIV. If they were still able to maintain a healthy enough 
body to work and get by, it was not yet necessary to contemplate a different course of action.  
However, once they are no longer able to work, the logic of denial ceased to be productive. As 
such health, or at least ‘good enough’ health, is defined by having more time. They are still healthy 
enough to justify living with ambiguity about their HIV status even if they have symptoms.  
The circumstances surrounding the decision to finally have an HIV test differed among 
participants. For some participants once they noticed that their symptoms were persistent and no 
longer manageable, they made a personal choice to go for HIV testing. A 43 year old man from 
Zimbabwe (WHO Stage 3), is an example: 
But when I realized that I was not getting better I said to myself let me go and have my 
blood checked. The first day I went but did not get in [HIV testing rooms] and I came back 
but then I regretted and that night it got worse I could not sleep and I said I am going back 
tomorrow so I gained the courage and that’s when I got tested.  
However, the decision to test was commonly framed as stemming from a recognition that they no 
longer had the option of pursuing any other course of action. Participants described their 
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circumstances or the unavoidable gravity of their ill health as an irresistible pressure. Their options 
and ‘time’ were running out.   
I was forced because I noticed that my health was becoming worse each day. The size I 
was at was reducing. I first got an illness that lasted sometime; the stomach would pain me 
so much but I refused to go to the hospital and instead used herbal treatment and I drank 
so much but the stomach refused [to get better]. (Male, 40 years, Uganda, WHO Stage 1) 
Some people developed what would otherwise be very serious illnesses such as meningitis and 
psychiatric problems but did not relate these illnesses to HIV.  In these cases, it was health workers 
that advised such participants to take an HIV test. For instance,  a 19-year-old man from Uganda, 
(WHO Stage 4) was brought by his mother to the hospital. He was later tested and was found to 
be HIV-positive. 
The head was paining very much and they removed some water [fluids] from the back [spine] 
and that is when the pain subsided. They diagnosed it as meningitis and started treatment. I 
spent two months on the ward and later a doctor took off my blood and they tested it and I 
was found to be HIV-positive 
A 38 year old man from Uganda (WHO Stage 4) had a similar experience after complaining of a 
headache and developing complications: 
But the problem was severe headache, so I was put on drip, I spent the night there as they 
put me on the drug. Then in the morning they examined my back and took off some water 
[fluids] from the spine and tested it and they told me that I had meningitis.  
There was a sub-group of participants who had already tested at an earlier point (months or 
sometimes years before) but had not taken up the opportunity for treatment until they joined this 
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trial. There were instances where the delays between testing and treatment were attributed to a lack 
of available treatment options, delays in laboratory monitoring or the return of CD4-test results or 
patients did not pursue a referral. However, for all of those who had previously received a positive 
test result, they had not considered that initiating treatment was urgent. So, a similar logic applied, 
even among those who had tested: until they got ill to the extent that it was unmanageable, they 
had more time.  
  
Having encountered problems accessing CD4 tests, many waited until they became sick before 
returning to seek any further care. In some cases, this meant considerable time had elapsed between 
receiving a positive test result and having a CD4- test done and then starting ART.  
There were some exceptions to this where individuals had initially received a positive test result 
and had a CD4 result which was, at that time, above the threshold for initiating ART. However, 
the pattern was that individuals were waiting until they became sick to re-engage with care. 
Clinically they were then classified as ‘late presenters’. A 53 year old woman from Zimbabwe 
(WHO Stage 3) said that:  
This year [2015] I fell sick and went to the clinic and they took a CD4 count. My results 
delayed coming out and I was told to come a week after, I went back after one week and I 
was told to come after two weeks. Then I was told I should come on a Monday and then on 
a Friday but I never got the results and I was getting frustrated then one nurse advised me 
to go to a different clinic. I then went with my husband and got tested and found that my 
CD4 count was 55 on the same day. 
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It’s ‘about time’: listening to others 
In all cases seeking testing or treatment was constructed as prescient and unavoidable. Although 
in some cases, as shown above, it was described as a personal decision to seek a test and/or to 
initiate treatment, in many cases this ‘individual’ decision to pursue this course of action was 
shaped by partners, relatives, neighbours and friends who argued them that it was ‘now time’ to 
act. The dwindling capacity of individuals to successfully manage the symptoms without ART 
meant that it became time to listen and accept the advice of others to act. The opportunity for 
maintaining health tended to have already passed, what would be clinically defined as ‘late’, as 
this group of  people were all symptomatic when presenting for testing. There was a gendered 
pattern to this. 
  
Most of the women in our study described getting tested and agreeing to initiate ART on their own 
accord or through receiving standardised health care for another condition, such as through 
antenatal care when pregnant. There were only a few women who reported going for a test upon 
the direct insistence of others that they must do so.  
I first got a miscarriage and was badly off. So I got some medicines from a clinic but that 
didn’t help. Then my mother came and said you should go to a hospital and they test you. 
That is because I didn’t have energy and had told her the problem that I got [miscarriage]. 
So I went to a testing centre and they tested me for HIV and found that I had it. [My mother] 
noticed that I didn’t have energy. For me I thought it was due to the miscarriage but also 
my husband died and he had HIV that is why my mother told me that you have to go [and be 
tested]. (Female, 30 years, Uganda, WHO Stage 2) 
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Across our study there was a pattern that men reported tending to only acknowledge the necessity 
of testing once they had become debilitated by ill health and no longer effectively able to function 
or had been repeatedly urged to test by family members. For some, in the face of failure to treat 
their condition any other way, ART became necessary to restore their health.   
But for me to come here, I had very serious headache, throbbing so much and I wasn’t able, 
so the neighbours came and removed me from down where I was and they brought me to 
hospital. My eyes became blind and I was really going to die. They took me to some clinic 
and had me tested and I had HIV. (Male, 38 years, Uganda, WHO Stage 4) 
 
Within our study, it was reported that couple-based testing was initiated by women. This was often 
only done after considerable resistance by the male partner and once other critical conditions were 
met, namely debilitated health as described above.   
My wife told me that I was losing weight and that I should be tested for HIV but I was not 
convinced as I didn’t realize it then that I was losing weight. I could still do my work. I don’t 
know what my wife had observed because she kept saying you need to go and see a doctor 
but I was not sick at the time. After sometime, that’s when I realized I was becoming weak 
and I started coughing. When I got worse that is when I went to the clinic with my wife and 
we were tested together for the first time (Male, 31 years, Zimbabwe, WHO Stage 1). 
 
Present when they are symptomatic and they have run out of ‘time’; when it is time to 
A key factor in the delay in seeking treatment was the fears which existed around both the 
consequences of testing and of treatment. Although ART had been available for many years, the 
immediacy of being able to start treatment did not necessarily allay the significance involved in 
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the recalibration of self-identity and risks to the self in doing so.  A 47 year old woman from 
Zimbabwe (WHO Stage 4) is one example: 
It is difficult to accept that status [HIV-positive] even though you will be looking back at 
your past behaviour and you might be suspecting it but you just don’t want that confirmation 
to say you have HIV. I once suspected it, there was a time about two years back when I got 
sick but was quick to dismiss it saying I have been bewitched. So, the issue of acceptance is 
what causes people to say ha it’s not HIV but just chest pains, you will just be suspicious but 
one can just say I was bewitched because we Africans believe in being bewitched. 
 
Following this logic, testing is scary because it confirms an HIV-positive status. However initiating 
treatment is also frightening because of the perceived related risks of being identified as HIV-
positive through attending the clinic and being seen to take the pills. It was described as 
burdensome in terms of time, but also in the unwelcome reliance on indefinite treatment in which 
their health would always subsequently be mediated by medication.  
 
An additional factor was participants’ concerns about the side effects that come with taking drugs. 
Many participants spoke about the negative stories which circulated about the effects of ART 
within the community. The response to these narratives though was varied. Some described that 
their fears of encountering difficulties with the treatment and causing resistance acted as a 
motivation to adhere well to their treatment. However, others described it as having put them off 
wanting to start ART at all. It was the possibility of ill health that convinced them of the necessity 
of treatment despite their fears, not because they had been persuaded of the treatment’s tolerability.   
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What I mostly feared was in the first place when they talked about these drugs that we take 
they would speak very harsh and scary words. Like, can you take ARVs; that tablet cannot 
go past the throat and even if it goes past, it is going to affect you and you will get 
transformed and become a nuisance, you will even grow a bump on the back. (Male 40 years, 
Uganda, WHO Stage 1) 
The dilemmas that these frightening narratives provoked, which may not be widely discussed or 
acknowledged within the clinical community, are described by a 40 year old man from Zimbabwe 
(WHO Stage 3):  
I hesitated to go on treatment after they [clinic staff] told me about the pills because people 
were saying the pills will make you mad you will not even sleep. Some people were saying 
you can dream about pigs and you will be shouting pigs, pigs pointing at them saying ‘see 
those pigs’ (laughs). But these issues are bad because they cause people to lose hope with 
the programme. People will be afraid of the programme [HIV treatment and care] because 
of what goes around in our communities. Even when I came here and I was given the pills I 
didn’t want to take them but my wife was the one who insisted saying, ‘you must not listen 
to what people say. What you want is to get better’. Plus the pain from the piles was troubling 
me, I then gained courage and said I want the piles to go away.    
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Discussion  
The biomedical logic within the era of test and treat is that HIV-related illnesses are essentially 
avoidable. Test and treat is all about maximizing the opportunity to retain health for the HIV-
positive individual who presents before they become severely sick and before their immune system 
is too damaged. Connected to this, onward transmission is also considered theoretically 
preventable as by being on treatment an individual can have an undetectable load and, if that is 
maintained, cannot infect others (Rodger et al., 2016). Within our sample, there were several 
people with substantial HIV-associated symptoms and a number with very high viral loads (Table 
2), although these were not necessarily the same people.  
 
However, our findings illustrate that the logic of the lived experience of those participating in our 
study is at odds with the biomedical logic of test and treat. We found that individuals do not 
consider themselves as presenting ‘late’ (or at least they do not prior to starting treatment), instead 
they present when it is absolutely necessary. The need to get onto treatment is not yet urgent if 
they consider themselves to have ‘more time’. There is a disparity between the clinical guidelines 
and the lay interpretations of our participants in what constitutes the criteria for it to be necessary 
to start treatment. This relates to a significant divergence in how ‘time’ is conceptualised as a 
resource for healthiness: how much time can be consumed once HIV-positive and still be 
considered ‘healthy’ without treatment. In our participants’ views the duration is more elastic and 
plentiful than indicated within the current clinical guidelines.  In addition, the changes in clinical 
messaging can take time to filter through to patients and the wider community; this is compounded 
by the relatively rapid clinical progress (and resultant changes to thresholds for starting treatment).   
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It is important to note that this study was conducted in 2014-2015 during the very early stages in 
the shift towards the policy of test and treat in both Uganda and Zimbabwe (test and treat was 
available for some key populations in 2014, but for the general population the implementation of 
the policy change was in 2016). We acknowledge that individuals may receive faster referrals for 
testing and then may be more proactively encouraged to rapidly initiate ART had we conducted a 
similar study today. As such, our study cannot act as an evaluation of the impact of the test and 
treat policy on potential ‘late presenters’. However, the contribution our study makes is in 
identifying important features of participants’ experiences of time in relation to their own health, 
as well as their expectations of what it entails to accept that they need to start ART. These in turn 
offer productive explanations for why people may present ‘late’. They are pertinent in informing 
how the message of the test and treat policy should be crafted to emphasise the advantages of 
starting ART as early as possible for an individual to maintain their health and protect others, in 
order to encourage earlier presentation amongst a greater number of people and thus optimise its 
success.  
 
Importantly we found that participants’ perceived sense of health may not be intrinsically disrupted 
by an individual’s implicit assumption that they have probably acquired HIV. The disruption 
appears to be embedded within the confirmation of an HIV-positive status and the push to initiate 
treatment. We argue that the time-lag that we have noted between participants appreciating their 
own likely positive status and acting on it tells us three things. First, that many of our participants 
do not necessarily expect or anticipate perfect health, but instead they need sufficient health to 
continue to function and in most cases, this means still being able to work or be ‘productive’ in 
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some form.   Second, and intrinsic to this, is appreciating that many people delay acting because 
they are not yet ready to accept their recalibrated identity (Russell et al., 2016). Starting treatment 
might improve their health, but initially at least it involves confronting a new identity which 
explicitly involves a liminal state of health.  Third, there is a tenacious concern as to what the 
impact of the treatment will be on their ‘life worlds’ and so people postpone engaging with HIV 
care until they need to do so and this is done to restore, rather than protect or maintain, their health.  
 
The definition of `good enough health’ for our participants is having time to act later. Having more 
or enough time is given as a justification for ‘delaying’ mostly because they feel ‘healthy’ and 
therefore can postpone testing and treatment. This has often been given as one of the reasons given 
by people who present late (Rangarajan et al., 2014; Siedner et al., 2015).  
 
Considering the time that it will take to allow people to reconcile themselves to their new 
confirmed reality that they are HIV-positive before initiating treatment has received relatively 
little attention within the shift towards test and treat (Mbonye et al., 2016). For some of the 
participants, their hesitancy related to feeling that they needed time to think about the 
consequences of being HIV-positive and starting treatment. The message of ART as a route to 
maintain a form of ‘complete’ health (i.e. the absence of initial or ongoing HIV-related illnesses) 
rather than an opportunity to restore health (Takarinda et al., 2015), has not yet percolated 
throughout communities in high-prevalence settings.   
In this study, there were no differences by gender in the state of health participants were in when 
they enrolled in the trial (nor were there differences across the three sites). All were enrolling 
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late, given the focus of the study, and both men and women presented when they were ill with 
many HIV-related symptoms. In addition, many of them had taken HIV tests and therefore knew 
they were HIV positive for quite some time before being enrolled onto the REALITY study. This 
means that they were aware of their risk but had not sought for treatment at this point. This can 
be attributed to treatment access because we note that from the narratives of these participants 
that an inability to immediately start on treatment contributed to their ill health, a finding 
corroborated in the work of Janet McGrath and colleagues (2012). 
 
 However, we found that women were more likely than men to endure severe symptoms for shorter 
periods and started treatment on their own initiative or because of antenatal care. Women also 
mentioned being encouraged by their friends or family to go and test once they had persistent and 
severe symptoms. So, while they presented `late’ in clinical terms they appeared to act more 
quickly than men when symptoms became severe.  
 
Men often put of seeking care until they were left with little choice but to go and test for HIV, 
many times at the insistence of their partners.  Some men presented with very severe illness 
because they had taken much longer to make the decision to test and seek for care, perhaps because 
of the fear of the diagnosis and the belief they were strong enough to manage their ill health (Siu, 
Seeley, & Wight, 2013). 
 
Therefore, challenges in reconciling a healthy body with lifelong treatment for an illness may be 
particularly gendered, as has been shown elsewhere (Parrott et al., 2011; Skovdal, Campbell, 
27 
 
Nyamukapa, & Gregson, 2011).   The messaging needs to be targeted, particularly towards men, 
including through workplace outreach, to confront the attitude that ART becomes a tolerable 
option only once they have become so ill that it substantially impedes their capacity to function 
and work. Testing and treatment outreach services needs to engage with local conceptualisations 
of masculinity which emphasise the attainment of health through ongoing productivity, even if that 
is supported by ongoing clinical treatment (Siu et al., 2013).  
 
Our findings also emphasis the outdated but pernicious concerns which circulate around the side-
effects of ART (Renju et al., 2017). Although many of these are now inaccurate, most of what the 
participants were referring to relates to the historical roots of earlier treatment where side-effects 
such as lipodystrophy were more common. Most treatments have now become much more 
tolerable, the physical signs that someone is on treatment and that ART is working are so 
‘undetectable’ that for some people, including many of those in our study who presented ‘late’, 
the community narratives about the harsh, risky effects of treatment are not changing because they 
do not ‘see’ those on the more recent, effective, invisible treatments. The perverse effects of the 
success of more recent ART is that those on ART are invisible and so the early examples of ART 
side effects remain the reference point through which some people assess the risks in starting on 
treatment.  
 
Failure to counteract and address these community narratives about the side effects of ART is 
likely to affect uptake of HIV testing and retention on treatment (Wringe, Renju, Seeley, 
Moshabela, & Skovdal, 2017). Again, the messaging around test and treat needs to place greater 
emphasis on the relative tolerability of ART, the protective opportunities of treatment as 
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prevention and the comparative absence of side-effects since the early days of HIV treatment 
availability in these settings. An essential component in incentivising early or timely initiation of 
ART is to emphasise the increased likelihood of not having physical markers of HIV and rendering 
HIV invisible if treatment is started as soon as possible.   
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